Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months
ABSTRACT: SARS-CoV-2 vaccines have shown very high effectiveness in real-world scenarios. However, there is compelling evidence for a fast-paced waning of immunity. The increasing number of new variants that could alter the severity, transmissibility, and potential to evade the immune response raise...
- Autores:
-
Lopera Restrepo, Tulio José
Medina Chvatal, Mateo
Flórez Álvarez, Lizdany
Zapata Cardona, María Isabel
Taborda Vanegas, Natalia Andrea
Rugeles López, María Teresa
Hernández López, Juan Carlos
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2022
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/35566
- Acceso en línea:
- https://hdl.handle.net/10495/35566
- Palabra clave:
- SARS-CoV-2
Vacunas contra la COVID-19
COVID-19 Vaccines
Anticuerpos Neutralizantes
Antibodies, Neutralizing
Inmunogenicidad Vacunal
Immunogenicity, Vaccine
Vacuna BNT162
BNT162 Vaccine
Estudios Prospectivos
Prospective Studies
Variant
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by/2.5/co/
